First-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

2015 • 5,267 citations

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

2018 • 3,846 citations

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

2019 • 2,714 citations

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

2019 • 2,100 citations

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

2018 • 1,067 citations

Systemic Therapy for Metastatic Renal-Cell Carcinoma

2017 • 1,066 citations

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

2019 • 853 citations

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

2017 • 550 citations

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

2018 • 326 citations

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

2017 • 276 citations

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

2017 • 275 citations

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial

2018 • 236 citations

Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy

2007 • 218 citations

Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence

2011 • 166 citations

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

2018 • 141 citations

Immune checkpoint inhibitors in cancer therapy

2017 • 136 citations

Immune checkpoint inhibitors in renal cell carcinoma

2017 • 83 citations

Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

2019 • 74 citations

Role of Radiation Therapy in the Management of Renal Cell Cancer

2011 • 60 citations

Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies

2015 • 51 citations

Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals

2018 • 47 citations

Therapeutic challenges in renal cell carcinoma.

2015 • 26 citations

KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)

2018 • 22 citations

Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial.

2018 • 10 citations

Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis

2015 • 8 citations